Durability of single-dose rVSV-ZEBOV vaccine responses: what do we know?

• Main Authors: Angela Huttner (Author), Claire-Anne Siegrist (Author)
• Format: Book
• Published: Taylor & Francis Group, 2018-12-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.
• Notes: 1476-0584; 1744-8395; 10.1080/14760584.2018.1546582
• Keywords: ebola virus disease; ebola vaccine; rvsv-zebov vaccine; immune response; durability; persistence; seropositivity; Internal medicine; RC31-1245
• Source: Expert Review of Vaccines, Vol 17, Iss 12, Pp 1105-1110 (2018)

Introduction: The live-attenuated recombinant vesicular stomatitis virus vaccine expressing the glycoprotein (GP) of Zaire Ebola virus (rVSV-ZEBOV) has proven immunogenic in humans and effective in field studies. Yet long-term durability of vaccine responses is unknown. Areas covered: We survey the evidence available in the literature for the durability of human responses to rVSV-ZEBOV. We also review determinants of initial responses and of their persistence. Expert commentary: Persistence of EBOV-GP-specific antibody responses is strong at 2 years - currently the longest post-vaccination interval studied - after a single injection. Vaccine dose predicts persistence of seropositivity, though the magnitude of antibody responses at later time points becomes less dose-dependent. Vaccine-related arthritis is a significant predictor of both persistence and magnitude of the antibody response.